Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"Gamma scintigraphic imaging was used to visualize in vivo performance of the enteric coated delayed release tablets designed to target delivery of Brilacidin (50mg, 100mg, and 200mg) to the colon. For Brilacidin treatments, radiolabel release was observed in the ascending colon for four out of the six subjects and in the terminal ileum and ileocecal junction for the remaining two. Following release, dispersion of the radiolabel was then observed throughout the colon."

I suppose it doesn't matter but they aren't reporting the location of the radiolabel release in the 3 placebo subjects. Could the graphic be one of those?
"A series of images from one Brilacidin study subject are provided below which illustrate the radiolabeled study oral tablet being successfully dispersed into the colon."


Is there a Doctor in the house? I can't tell if the graphic depicts release in the ileocecal junction or the ascending colon.
https://www.anatomynote.com/human-anatomy/digestive-system-anatomy/ileocecal-junction-anatomy/


Would the different dosages appear differently in the imagery, as in lower dosages providing less coverage, or would the dispersion appear the same and the "only" difference be in the efficacy?


There were only 9 subjects.....more imagery would be interesting and informative. Website space is cheap. If this study was as important as suggested I hope they'll use it. BDD simply added the IPIX PR to its website, adding nothing.
More to follow?